Accessibility Menu
BioForce Nanosciences logo

BioForce Nanosciences(OTC) BFNH

Current Price$1.25
Market Cap$41.94MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2006)+150%
5 Year+4%
1 Year+67%
1 Month-24%
BioForce Nanosciences last closing stock price
MetricPriceDate
Last closeUSD 1.252026-07-23
BioForce Nanosciences stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-16.67%USD 1.502026-07-16
1 month-24.24%USD 1.652026-06-23
3 month+82.14%USD 0.692026-04-23
Year to date+116.26%USD 0.582025-12-29
1 year+66.67%USD 0.752025-07-18
3 year-44.69%USD 2.262023-07-24
5 year+4.17%USD 1.202021-07-14
Since inception+150%USD 0.502006-02-21

BioForce Nanosciences Financials at a Glance

Market Cap

$41.94MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$458.91K

EPS (TTM)

-$0.01

P/E Ratio

-91.24

Dividend

$0.00

Beta (Volatility)

-0.42 (Low)

Price

$1.25

Volume

1,200

Open

$1.26

Previous Close

$1.25

Daily Range

$1.25 - $1.26

52-Week Range

$0.18 - $2.05

Estimated Earnings Date

May 19, 2026

BFNH News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About BioForce Nanosciences

BioForce makes natural vitamins and supplements for people of all ages. Its products aim to support daily nutrition and active lifestyles. Customers use these supplements to fill dietary gaps or boost wellness routines.

What’s in the Bottle? Products and Services

  • Natural vitamins and minerals: Supplements designed for general health, targeting adults and athletes. (0% of revenue in 2025)
  • Powdered nutritional supplements: Multi-vitamin and mineral powders for mixing with drinks. (0% of revenue in 2025)
  • Beverages: Ready-to-drink nutritional products for on-the-go use. (0% of revenue in 2025)
  • Private label services: Custom-branded supplements for retailers and gyms. (0% of revenue in 2025)
  • Online and retail sales: Products sold through stores, gyms, and online platforms. (0% of revenue in 2025)

Growth and Expansion: The Road So Far

  • Launched the BioForce Eclipse supplement line; no sales reported as of 2025.
  • Entered private label agreements with a Virginia-based manufacturer (year not specified).
  • Expanded planned distribution to supermarkets, sporting goods stores, and online channels.
  • Maintains a wholly-owned subsidiary, Element Global, for potential acquisitions in media and sports (no revenue contribution).
  • Plans to introduce biodegradable packaging and expand product lines under BioForce Eclipse.

What Makes BioForce Stand Out?

BioForce uses a consignment model, paying suppliers only when products sell. The company targets both traditional supplement users and broader fitness markets through private label flexibility.

Five Things You Need to Know

  • No revenue or unit sales reported in 2025 or 2024.
  • Net loss was $1.29 million in 2025, up 163% from 2024.
  • Operating expenses remained flat at about $490,000 in 2025.
  • Cash balance was $786 at year-end 2025, with a $618,543 working capital deficit.
  • Three full-time employees manage all operations and strategy.

Bottom Line

BioForce remains in early stages, with no sales and ongoing losses. Its future depends on overcoming market entry and funding challenges.

AI Generated • Apr 16, 2026

Industry

Personal Products

Sector

Consumer Staples

Employees

3

CEO

Steven F. Gagnon; John S. LaViolette

Website

bioforceeclipse.com

Headquarters

Virginia Beach, VA 23454, US

BFNH Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

82.56%

Return on Capital

N/A

Return on Assets

-7230.27%

Earnings Yield

-1.10%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$41.94MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

33.55M

Volume

1.20K

Avg. Volume

4.60K

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$474.23K

EBITDA

-$474.23K

Operating Cash Flow

-$42.85K

Capital Expenditure

$0.00

Free Cash Flow

-$42.85K

Cash & ST Invst.

$6.35K

Total Debt

$99.76K

BioForce Nanosciences Performance Analysis

BioForce Nanosciences annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
BioForce Nanosciences sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
BioForce Nanosciences annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.02-3.5%
20232023-12-31USD -0.02-3.0%
20242024-12-31USD -0.024.3%
20252025-12-31USD -0.04131.5%
BioForce Nanosciences sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3087.2%
Q32025-09-305.4%
Q42025-12-31N/A
Q12026-03-3111.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$41.94MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$13.98M

N/A

Employees

3

N/A

Net Income

-$102.41K

+89.0%

EBITDA

-$117.73K

+11.8%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$6.35K

-54.0%

Total Debt

$99.76K

+136.3%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$99.76K

+136.3%

Return on Assets

-72.30%

N/A

Return on Invested Capital

65.78%

N/A

Free Cash Flow

$7.09K

+146.6%

Operating Cash Flow

$7.09K

+146.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
NPRFFNepra Foods Inc.
$0.20-5.33%
ELAMFElamex S.A. de CV
$2.81+0.36%
DTEAFDAVIDsTEA Inc.
$0.63+0.00%
IRCKFInter-Rock Minerals Inc.
$0.77+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.76-0.29%
INTCIntel
$100.23-0.02%
AALAmerican Airlines Group
$13.56-0.08%
SMCISuper Micro Computer
$31.20+0.02%

Questions About BFNH

What is the current price of BioForce Nanosciences?

BioForce Nanosciences is trading at $1.25 per share.

What is the 52-week range for BioForce Nanosciences?

Over the past 52 weeks, BioForce Nanosciences has traded between $0.18 and $2.05.

How much debt does BioForce Nanosciences have?

As of the most recent reporting period, BioForce Nanosciences reported total debt of $0.00.

How much cash does BioForce Nanosciences have on hand?

BioForce Nanosciences reported $6.35K in cash and cash equivalents in its most recent financial results.

What is BioForce Nanosciences’s dividend yield?

BioForce Nanosciences does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services